New Onset Diabetes Mellitus and Cardiovascular Events in Korean Patients with Acute Myocardial Infarction Receiving High-Intensity Statins

Jah Yeon Choi  
Korea University Guro Hospital

Cheol Ung Choi  (wmagpie@korea.com)  
Korea University Guro Hospital  https://orcid.org/0000-0003-2815-9358

Byoung Geol Choi  
Korea University Guro Hospital

Yoonjee Park  
Korea University Guro Hospital

Dong Oh Kang  
Korea University Guro Hospital

Won Young Jang  
Catholic University of Korea St.Vincent Hospital

Woohyeun Kim  
Korea University Guro Hospital

Jin Oh Na  
Korea University Guro Hospital

Jin Won Kim  
Korea University Guro Hospital

Eung Ju Kim  
Korea University Guro Hospital

Seung-Woon Rha  
Korea University Guro Hospital

Chang Gyu Park  
Korea University Guro Hospital

Hong Seog Seo  
Korea University Guro Hospital

Myung Ho Jeong  
Chonnam National University Hospital

Sung-Chull Chae  
Kyungbook National University Hospital

In-Whan Seong
Chungnam National University School of Medicine

Chang-Hwan Yoon
Seoul National University Bundang Hospital

Kwang Soo Cha
Pusan National University School of Medicine

Seok Kyu Oh
Wonkwang University School of Medicine Hospital

Research article

Keywords: acute myocardial infarction, new-onset diabetes mellitus, cardiovascular outcome, atorvastatin, rosuvastatin

Posted Date: January 5th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-35963/v4

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on February 4th, 2021. See the published version at https://doi.org/10.1186/s40360-021-00476-z.
Abstract

Background: High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period. Methods: Data from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2,221 patients without diabetes who had been administered with high-intensity atorvastatin (40–80 mg) and rosuvastatin (20 mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years. Results: Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM and MACE was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. Conclusions: Administering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.

Background

Statins typically prevent cardiovascular events by lowering total and low-density lipoprotein (LDL) cholesterol levels in the serum. Considering their rapid and sustained clinical advantages, the current guideline recommends administration of high-intensity statins in patients with acute myocardial infarction (AMI) for secondary prevention. However, there has been consistent concern regarding its association with new-onset diabetes mellitus (NODM).[1] Clinical trials, meta-analyses of randomized controlled trials (RCTs), and observational studies have demonstrated a 10%–12% increase in NODM among patients receiving statins.[2, 3] Meta-analysis of five large-scale trials comparing intensive and moderate doses of statins have demonstrated that the risk of NODM further increases in intensive therapy groups.[4] However, it is unclear if the diabetogenic effect of statins is a class effect. Considering their crucial role of secondary prevention in patients with AMI, it would be important to identify the diabetogenic and cardioprotective effects of high-intensity statins. In Korea, atorvastatin 40–80 mg and rosuvastatin 20 mg are currently available as high-intensity statins for clinical use. Here, we investigated the effect of high-intensity atorvastatin and rosuvastatin on cardiovascular outcomes and NODM in patients with AMI over a 3-year follow-up period.

Methods

Data collection and study population
The Korea Acute Myocardial Infarction Registry (KAMIR), a Korean prospective, multicenter, nationwide database supported by the Korean Society of Cardiology, reflects real-world treatment practices and outcomes in Asian patients diagnosed with AMI. Twenty university or community hospitals have participated in the registry. Data collection at the institution level is performed by a well-trained study coordinator using a standardized case report form. The collected data are managed using web-based systems. All participants provided written informed consent, and the study was approved by the ethics committee at each participating institution.

A total of 13,104 patients with AMI were enrolled in the KAMIR registry between November 2011 and October 2015. A total of 6,728 patients without a history of diabetes mellitus (DM) with successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation and high-intensity statin treatment were eligible for our study. Patients were selected considering the following exclusion criteria: history of DM or initial HbA1c level ≥ 6.5%, bare metal stent implantation, plain old balloon angioplasty, or failed PCI. Additionally, we did not include patients with in-hospital major adverse cardiac events (MACE) to specifically include AMI survivors. Finally, 2,221 patients with AMI treated with high-intensity atorvastatin or rosuvastatin, according to 2014 ACC/AHA Release Updated Guideline, were enrolled in this study. Of them, 60.7% (1,349/2,221) of patients had received 40–80 mg atorvastatin and 39.3% (872/2,221) had received 20 mg rosuvastatin (Fig. 1).

Clinical outcome and definition

The primary endpoint was the incidence of NODM and the incidence of MACE during the 3 years of clinical follow-up. Secondary endpoints were each component of MACE, reasons for mortality, MI, and revascularization. NODM was defined as an HbA1c level ≥ 6.5% or new administration of oral hypoglycemic agents. Clinical data of the enrolled patients were obtained through face-to-face interviews during regular outpatient visits, medical chart reviews, and telephonic interviews.

Statistical analysis

For continuous variables, differences between the two groups were evaluated by Student’s t-test. Data were expressed as mean ± standard deviation (SD). For discrete variables, differences were expressed as counts and percentages and analyzed using the Chi-square test or Fisher’s exact test. The cumulative incidence of NODM and MACE was estimated using the Kaplan–Meier method, and the intergroup differences were determined using the log-rank test. Cox-proportional hazard models were used to identify potential prognostic factors for NODM and MACE and assess the hazard ratio (HR) of the atorvastatin group compared with the rosuvastatin group. Multivariate analysis was performed by including variables with significant P-values in the univariate analysis (P < 0.05). For all analyses, a P-
value < 0.05 was considered statistically significant. The data were processed using SPSS (version 22.0, Inc Chicago, IL).

**Results**

**Baseline characteristics**

Baseline clinical, laboratory, and angiographic characteristics are shown in Table 1. We did not observe any significant intergroup differences with regard to age, gender, LV systolic function, incidence of STEMI, and underlying diseases such as hypertension and cerebrovascular accidents. Patients in the rosuvastatin group had higher levels of LDL cholesterol and peak CK-MB and a longer total stent length than those in the atorvastatin group. Dual antiplatelet therapy (DAPT) rate was above 99% in both groups; however, the composition of DAPT was different in that the prescription rate of prasugrel was higher in the atorvastatin group and that of ticagrelor was higher in the rosuvastatin group. Numbers of patients taking ACEi or ARB and β blockers were higher in the atorvastatin group than in the rosuvastatin group.

**Clinical outcomes**

Kaplan–Meier curves for the cumulative incidence of NODM up to 3 years are presented in Fig. 2A and Table 2. There was no significant difference in the event-free survival rate of NODM between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). Kaplan–Meier curves for the cumulative incidence of MACE up to a period of 3 years are presented in Fig. 2B and Table 2. There was no significant difference between the atorvastatin and rosuvastatin groups regarding the event free survival rate of MACE (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662), reasons for mortality, myocardial infarction, and revascularizations. Comparing 40 mg and 80 mg of atorvastatin groups with 20 mg of rosuvastatin group revealed no significant differences in the event-free survival rate of NODM and MACE (see Additional file 1: Fig. S1A and B).

Potential prognostic factors for NODM were identified via univariate Cox regression analysis. Higher random glucose and triglyceride levels were both significant prognostic factors for NODM in univariate and multivariate analysis. However, the type of statin used was not (HR = 1.098, 95% confidence interval [CI]: 0.808–1.491, P = 0.551, Table 3). Conventional risk factors including older age, lower left ventricular ejection fraction (LVEF), and higher creatinine levels were associated with a higher incidence of MACE. Use of new antiplatelet agents such as ticagrelor or prasugrel was a significant prognostic factor in univariate analysis, not however, in the multivariate analysis. The type of high-intensity statin, atorvastatin or rosuvastatin, was not a potential prognostic factor for MACE (HR = 0.944% confidence interval [CI]: 0.727–1.225, P = 0.662, Table 3).

**Discussion**
To the best of our knowledge, this is the first study to investigate the effect of high-intensity statin treatment on the development of NODM and MACE in Korean patients with AMI. Our results indicated that high-intensity atorvastatin and rosuvastatin therapies showed no significant difference with regard to the incidence of NODM and cardiovascular events.

Statins reduce serum LDL cholesterol level and the risk of cardiovascular events. As numerous studies revealed that the degree of cardiovascular risk reduction is proportional to the statin intensity, [5, 6] the current guidelines strongly recommend high-intensity or maximally tolerated intensity statin therapy in patients with AMI in the absence of contraindications.[7, 8] However, several studies have suggested that statins increase the incidence of NODM.[3, 9] The issue has started attracting attention since the Justification for the Use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial reported a higher incidence of NODM in patients treated with rosuvastatin for primary prevention than in patients with placebo.[10] Numerous observational studies [11, 12] and meta-analyses of major RCT [3, 13] have consistently reported an increased incidence of NODM in patients receiving statin treatment. In Korea, a population-based cohort study using the Korean National Health Insurance claims database has shown an increased incidence of NODM in statin-treated groups.[2]

Whether the diabetogenic effect of statin is a class effect has been a controversial subject. Typically, atorvastatin and rosuvastatin are thought to unfavorably influence glycemic parameters, while pitavastatin and pravastatin have relatively neutral effects on glycemic control regardless of the presence or absence of DM.[1] Our group recently published a report regarding the favorable glycemic effects of moderate-intensity pitavastatin in comparison to those of moderate-intensity atorvastatin and rosuvastatin in patients with AMI.[14] Despite the current guidelines recommending high-intensity or maximally tolerated statin for secondary prevention in patients with AMI,[7, 8] there is no study, to the best of our knowledge, that has compared the diabetogenic effects of different high-intensity statins.

Several studies were conducted regarding the cardiovascular outcomes after high-intensity statin therapy. In patients with acute coronary syndrome, both the atorvastatin and rosuvastatin groups had comparable effects on lipid parameters,[15, 16] although patients with familial hypercholesterolemia in the rosuvastatin group demonstrated a greater reduction in LDL cholesterol levels than those in the atorvastatin group.[17] Some studies have reported more favorable effects of rosuvastatin on reducing atherosclerotic plaque volume [15, 18] and plaque stabilization [15] than of atorvastatin; however, there has been no significant difference with regard to the cardiovascular outcome in both groups.[17, 19] In line with these previous studies, we could not identify the differences between the effects of high-intensity atorvastatin and rosuvastatin administration on major cardiovascular events.

Several studies have suggested the possible mechanisms underlying the effect of statin on glucose metabolism. Some studies have suggested the interconnection between glucose and lipid metabolisms by demonstrating gene variants affecting glucose metabolism,[20-22] cholesterol-dependent conformational change in glucose transporter protein,[23] or deleterious effect on islet β cells [24] by
statins. There is a scarcity of data regarding the mechanisms underlying the different diabetogenic effects of statins; hence, further study would be needed.

This study has several limitations. First, our study is not an RCT, which inevitably leads to selection bias and an imbalance in baseline characteristics. However, as KAMIR is a prospective registry that enrolls Korean patients with AMI, it can represent real-word clinical data. Second, there is a lack of data on rosuvastatin 40 mg and a relatively small number of patients have been treated with atorvastatin 80 mg; hence, dose-dependent increases in NODM could not be demonstrated in our study. Third, this study lacks data regarding the compliance of statin during the follow-up period. Most conventional variables such as age, LVEF, renal function, and new antiplatelet agents were shown to be significant prognostic factors for cardiovascular outcomes, but RAS blockers and β blockers were reported as modest and insignificant prognostic factors, respectively. Despite its limitations, to the best of our knowledge, this is the first study from a multicenter registry that demonstrated detailed real-world data on the effect of high-intensity statin on incidence of NODM and MACE in patients with AMI.

**Conclusions**

In conclusion, high-intensity atorvastatin therapy showed similar incidence of NODM and cardiovascular events when compared with high-intensity rosuvastatin therapy in patients with AMI. Although prospective, randomized trials with a larger study population are needed to clarify our results, the outcomes presented here provide supportive evidence for the diabetogenic and cardioprotective effects of high-intensity statins in patients with AMI.

**List Of Abbreviations**

AMI: acute myocardial infarction; KAMIR: Korea Acute Myocardial Infarction Registry; LDL: low-density lipoprotein; MACE: major adverse cardiac events; NODM: new-onset diabetes mellitus; PCI: percutaneous coronary intervention; RCT: randomized controlled trial

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Institutional Review Board of Korea University (IRB No. 2016GR0740) and all participants provided written informed consent.

**Consent for publication**

Not applicable
Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available because the KAMIR data is confidential and the approval was obtained for this specified topic.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by a fund (2016-ER6304-02) by Research of Korea Centers for Disease Control and Prevention.

Authors' contributions

JYC : conception and design of the work, acquisition/analysis/interpretation of data, writing- Original draft preparation, BGC : acquisition/analysis/interpretation of data, YP, DOK, WYJ, and WK : acquisition/analysis of data, JON, JWK, EJK, SWR, CGP and HSS : acquisition of data, MHJ, SCC, IWS, CHY, KSC, SKO : conception of the work, acquisition of data, CUC : conception and design of the work, supervision, reviewing and editing, acquisition/analysis of data.

Acknowledgements

This study was done with the support of Korean Circulation Society (KCS). The KAMIR study group of the KSC was as follows: Woong Chol Kang, Gachon University Gil Medical Center, Incheon; Kiyuk Chang, Catholic University Hospital, Seoul; Seung Ho Hur, Keimyung University Dongsan Medical Center, Daegu; Seung Woon Rha, Korea University Guro Hospital, Seoul; Kwang-Soo Cha, Pusan National University Hospital, Busan; Hyeon Cheol Gwon, Samsung Medical Center, Seoul; Seok Kyu Oh, Wonkwang University Hospital, Iksan; Jei Keon Chae, Chonbuk National University Hospital, Jeonju; Kyung-Kook Hwang, Chungbuk National University Hospital, Chungju; Chong Jin Kim, East West Neo Medical Center, Seoul; Jung Han Yoon, Wonju Severance Christian Hospital, Wonju; Jin Yong Hwang, Gyeongsang National University Hospital, Jinju; Doo Il Kim, Inje University Busan Paik Hospital, Busan; Seung Jae Joo, Jeju National University Hospital, Jeju.

We would like to thank Editage (www.editage.co.kr) for English language editing.
1. Betteridge DJ, Carmena R: The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol 2016, 12(2):99-110.

2. Lee J, Noh Y, Shin S, Lim HS, Park RW, Bae SK, Oh E, Kim GJ, Kim JH, Lee S: Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database. Ther Clin Risk Manag 2016, 12:1533-1543.

3. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW et al: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 2010, 375(9716):735-742.

4. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS et al: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. Jama 2011, 305(24):2556-2564.

5. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T et al: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54(4):293-302.

6. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48(3):438-445.

7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA et al: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020, 41(1):111-188.

8. Grundy SM, Stone NJ, Bailey AL, Beam C, Birchter KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al: 2018 AHA/ACC/AACVPR/APA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019, 73(24):e285-e350.

9. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32(10):1924-1929.

10. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. The Lancet 2012, 380(9841):565-571.

11. Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC: Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country. PLoS One 2013, 8(8):e71817.
12. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM: Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610.

13. Maruyama T, Takada M, Nishibori Y, Fujita K, Miki K, Masuda S, Horimatsu T, Hasuike T: Comparison of Preventive Effect on Cardiovascular Events With Different Statins. Circulation Journal 2011, 75(8):1951-1959.

14. Choi JY, Choi CU, Hwang SY, Choi BG, Jang WY, Kim DY, Kim W, Park EJ, Lee S, Na JO et al: Effect of Pitavastatin Compared with Atorvastatin and Rosuvastatin on New-Onset Diabetes Mellitus in Patients With Acute Myocardial Infarction. Am J Cardiol 2018, 122(6):922-928.

15. Thondapu V, Kurihara O, Yonetsu T, Russo M, Kim HO, Lee H, Soeda T, Minami Y, Jang IK: Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization. Am J Cardiol 2019, 123(10):1565-1571.

16. Altunkeser BB, Tuncez A, Ozturk B, Tezcan H, Ates MS, Yilmaz C, Yalcin MU, Aygul N, Demir K: Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome. Coron Artery Dis 2019, 30(4):285-290.

17. Perez de Isla L, Arroyo-Olivares R, Muniz-Grijalvo O, Diaz-Diaz JL, Zambon D, Fuentes F, Sanchez Munoz-Torrero JF, Mediavilla JD, Gonzalez-Estrada A, Miramontes-Gonzalez JP et al: Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. J Clin Lipidol 2019, 13(6):989-996.

18. Kumar A, Shariff M, Doshi R: Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials. Eur J Prev Cardiol 2019:2047487319868035.

19. Perez-Calahorra S, Laclaustre M, Marco-Benedi V, Pinto X, Sanchez-Hernandez RM, Plana N, Ortega E, Fuentes F, Civeira F: Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids Health Dis 2019, 18(1):216.

20. Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hyppönen E, Power C et al: PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. The Lancet Diabetes & Endocrinology 2017, 5(2):97-105.

21. Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, Luan J, Ardanaz E, Arriola L, Balkau B et al: Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA 2016, 316(13):1383-1391.

22. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S et al: Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. The New England journal of medicine 2016, 375(22):2144-2153.

23. Nowis D, Malenda A, Furs K, Oleszczak B, Sadowski R, Chlebowska J, Firczuk M, Bujnicki JM, Staruch AD, Zagozdzon R et al: Statins impair glucose uptake in human cells. BMJ open diabetes research & care 2014, 2(1):e000017.

24. Sampson UK, Linton MF, Fazio S: Are statins diabetogenic? Curr Opin Cardiol 2011, 26(4):342-347.
Tables

Table 1. Baseline clinical characteristics and angiographic and procedural characteristics
| Variables                        | Atorvastatin (n=1349) | Rosuvastatin (n=872) | P-value |
|---------------------------------|------------------------|-----------------------|---------|
| **Men**                         | 1105 (81.9%)           | 720 (82.6%)           | 0.693   |
| Age (years)                     | 61.0 ± 12.5            | 61.0 ± 12.6           | 0.918   |
| LV ejection fraction (%)        | 54.1 ± 9.9             | 54.0 ± 9.6            | 0.906   |
| Body mass index (kg/m²)         | 24.5 ± 3.2             | 24.4 ± 3.4            | 0.442   |
| **Myocardial infarction**       |                        |                       |         |
| ST-segment elevation            | 719 (53.3%)            | 478 (54.8%)           | 0.483   |
| Non-ST-segment elevation        | 630 (46.7%)            | 394 (45.2%)           |         |
| **Hypertension**                | 549 (40.7%)            | 329 (37.7%)           | 0.162   |
| Cerebrovascular accidents       | 42 (3.1%)              | 29 (3.3%)             | 0.781   |
| Total cholesterol (mg/dl)       | 195.5 ± 42.0           | 196.6 ± 45.6          | 0.563   |
| Triglyceride (mg/dl)            | 146.5 ± 120.3          | 145.4 ± 139.1         | 0.852   |
| HDL-cholesterol (mg/dl)         | 44.1 ± 11.1            | 44.0 ± 11.1           | 0.790   |
| LDL-cholesterol (mg/dl)         | 126.5 ± 36.3           | 130.6 ± 40.3          | 0.020   |
| CK-MB (mg/dl)                   | 125.2 ± 159.2          | 139.9 ± 145.1         | 0.029   |
| Glucose (mg/dl)                 | 136.7 ± 37.4           | 138.8 ± 37.9          | 0.216   |
| Creatinine (mg/dl)              | 0.97 ± 0.94            | 0.94 ± 0.42           | 0.340   |
| **Discharge medications**       |                        |                       |         |
| Aspirin                         | 1343 (99.6%)           | 865 (99.2%)           | 0.280   |
| Clopidogrel                     | 855 (63.4%)            | 473 (54.2%)           | <0.001  |
| Prasugrel                       | 188 (13.9%)            | 68 (7.8%)             | <0.001  |
| Ticagrelor                      | 302 (22.4%)            | 325 (37.3%)           | <0.001  |
| Cilostazol                      | 57 (4.2%)              | 29 (3.3%)             | 0.283   |
Calcium channel blockers  63 (4.7%)  45 (5.2%)  0.600

β blockers  1181 (87.5%)  714 (81.9%)  <0.001

ACEi  687 (50.9%)  321 (36.8%)  <0.001

ARB  426 (31.6%)  336 (38.5%)  0.001

**Procedural characteristics**

|                      | Atorvastatin | Rosuvastatin | P-value |
|----------------------|--------------|--------------|---------|
| Total stent length (mm) | 27.6 ± 12.2  | 39.8 ± 13.4  | <0.001  |
| Total stent number    | 1.17 ± 0.41  | 1.20 ± 0.45  | 0.077   |
| Stent diameter (mm)   | 3.20 ± 0.44  | 3.14 ± 0.44  | 0.062   |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CK-MB, Creatine Kinase-MB; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LV, left ventricle

**Table 2. Cardiovascular Outcomes at 3 Years**

| Clinical outcome                      | Atorvastatin | Rosuvastatin | P-value |
|---------------------------------------|--------------|--------------|---------|
| New onset diabetes mellitus           | 99 (7.5%)    | 70 (9.2%)    | 0.550   |
| MACE                                  | 149 (11.0%)  | 91 (10.4%)   | 0.662   |
| All cause of mortality                | 49 (3.6%)    | 25 (2.9%)    | 0.335   |
| Cardiac death                         | 19 (1.4%)    | 14 (1.6%)    | 0.710   |
| Non-cardiac death                     | 30 (2.2%)    | 11 (1.3%)    | 0.103   |
| Any myocardial infarction             | 30 (2.3%)    | 15 (1.8%)    | 0.409   |
| STEMI                                 | 8 (0.6%)     | 1 (0.1%)     | 0.083   |
| NSTEMI                                | 22 (1.7%)    | 14 (1.6%)    | 0.956   |
| Any revascularization                 | 98 (7.4%)    | 62 (7.2%)    | 0.892   |
| TLR                                   | 24 (1.9%)    | 21 (2.5%)    | 0.312   |
| TVR                                   | 48 (3.7%)    | 34 (4.0%)    | 0.692   |
| NTVR                                  | 51 (3.9%)    | 31 (3.7%)    | 0.788   |
| Stroke                                | 27 (2.0%)    | 10 (1.2%)    | 0.127   |

MACE, major adverse cardiovascular event; STEMI, ST-segment elevation myocardial infarction; NSTEMI, Non-ST-segment elevation myocardial infarction; NTVR, non-target vessel revascularization; TLR, target lesion revascularization; TVR, target vessel revascularization
Table 3. Cox regression of clinical outcome

|                      | Univariable |           |           | Multivariable |           |           |
|----------------------|-------------|-----------|-----------|---------------|-----------|-----------|
|                      | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | P-value |          |           |
| **NODM**             |             |           |           |               |           |           |
| Age                  | 0.988 (0.976–1.000) | 0.052 |          |               |           |           |
| Male gender          | 1.307 (0.848–2.013) | 0.225 |          |               |           |           |
| Glucose              | 1.009 (1.006–1.011) | <0.001 | 1.009 (1.006–1.011) | <0.001 |          |           |
| Triglyceride         | 1.001 (1.000–1.002) | 0.011 | 1.001 (1.000–1.002) | 0.021 |          |           |
| β blocker            | 0.768 (0.517–1.139) | 0.189 |          |               |           |           |
| Statin type          | 1.098 (0.808–1.491) | 0.551 |          |               |           |           |
| **MACE**             |             |           |           |               |           |           |
| Age                  | 1.026 (1.016–1.037) | <0.001 | 1.020 (1.009–1.032) | 0.001 |          |           |
| Male gender          | 0.964 (0.695–1.336) | 0.824 |          |               |           |           |
| LVEF                 | 0.974 (0.961–0.986) | <0.001 | 0.980 (0.966–0.993) | 0.003 |          |           |
| Glucose              | 1.003 (1.000–1.006) | 0.089 |          |               |           |           |
| Creatinine           | 1.155 (1.080–1.235) | <0.001 | 1.204 (1.062–1.364) | 0.004 |          |           |
| LDL cholesterol      | 0.995 (0.992–0.999) | 0.011 | 0.998 (0.994–1.002) | 0.258 |          |           |
| Statin type          | 0.944 (0.727–1.225) | 0.662 |          |               |           |           |
| Ticagrelor or prasugrel | 0.685 (0.522–0.899) | 0.006 | 0.784 (0.585–1.051) | 0.104 |          |           |
| ACEi or ARB          | 0.761 (0.569–1.018) | 0.066 |          |               |           |           |
| β blocker            | 0.855 (0.609–1.201) | 0.367 |          |               |           |           |

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LDL, low-density lipoprotein; LVEF, left ventricle ejection fraction

Figures
Figure 1

Patient flow chart AMI: Acute myocardial infarction, DM: diabetes mellitus, KAMIR: Korea Acute Myocardial Infarction Registry, MACE: major adverse cardiac events, PCI: percutaneous coronary intervention, POBA: plain old balloon angioplasty

Figure 2

A. New Onset Diabetes Mellitus

B. Major Adverse Cardiac Events

Log Rank $p = 0.550$

Log Rank $p = 0.662$
Kaplan–Meier curves for event-free survival rate of new-onset diabetes mellitus (A) and major adverse cardiac events (B) according to statin type

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx